How Is Chimeric Therapeutics’ CAR-T Therapy Shrinking Tumors at Dose Level 2?

middle.news 9:06am on Monday 4th of August, 2025 AEST • Healthcare Read Story

How Is Chimeric Therapeutics’ CAR-T Therapy Shrinking Tumors at Dose Level 2?

9:06am on Monday 4th of August, 2025 AEST Key Points CHM CDH17 advanced to 150 million CAR-T cells dose level 2 Early anti-tumor activity observed with 12% tumor shrinkage at dose level 2 No new safety concerns or off-target effects reported Dose level 1 patient shows durable stable disease with 18% tumor shrinkage at 8 months Read Story

middle. Tap to Read Tap the card to read the full analysis about CHM OPEN ARTICLE